127033-12-9

Upstream product

• 371-41-5 4-Fluorophenol 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 99183-99-0 4-chloro-7-methoxy-2,3-dihydro-1H-inden-1-one 
• 127033-13-0 4-fluoro-7-methoxy-1-indanone 
• 161178-24-1 7-fluoro-2,3-dihydro-1H-inden-4-ol 
• 136191-16-7 4-Fluoro-7-hydroxy-indan-1-one 
• 81945-10-0 4-chloro-7-hydroxy-2,3-dihydro-1H-inden-1-one 

Relevant academic research and scientific papers

Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors

With the goal of improving metabolic stability and further enhancing FBPase inhibitory activity, a series of tricyclic 8H-indeno[1,2-d][1,3]thiazoles was designed and synthesized with the aid of structure-based drug design. Extensive SAR studies led to th

6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

A 6-oxo-1,6-dihydropyridazine derivative, a preparation method therefor and medical use thereof, in particular, a 6-oxo-1,6-dihydropyridazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, and use thereof as a NaV inhibitor and use thereof in the preparation of a drug for the treatment and/or prevention of pain and pain-related diseases. Each substituent in general formula (I) is the same as defined in the description.

Compound and application of compound in preparation of medicines

The invention discloses a compound and its application in a medicine. the invention specifically provides a compound as shown in the formula (I) or a stereisomer, a geometrical isomer, a tautomer, a racemate, nitric oxide, hydrate, a solvate, a metabolite, pharmaceutically acceptable salts or a prodrug of the compound as shown in the formula (I). The invention also discloses an application of the compound in preparation of a medicine. The medicine is used in treating cancers.

Bicyclic amino-substituted compounds

A compound of formula (I), wherein X is O, CH 2, S, SO or SO 2 ; R is F or Cl; R 1 is H, C 1 -C 6 alkyl or C 2 -C 6 alkenyl; R 2 is H, C 1 -C 6 alkyl or C 2 -C 6 alkenyl; R 3 is H, C 1 -C 6, alkyl, a pharmaceutically acceptable salt thereof, an enantiomer thereof, and a pharmaceutically acceptable salt of said enantiomer for use in therapy. A pharmaceutical preparation containing as active ingredient any one of said compounds. A process for the preparation of a compound of formula (I).